All sessions will be held at the Faculty of Chemistry, Univesity of Belgrade
The program may be updated. Stay tuned!
Saturday, September 2, 2023
| 08.00 - 19.00 |
Participant registration |
| 09.00 - 19.15 | Opening ceremony |
| 09.15 - 10.45 | Christel Bergström, Uppsala University, Sweden Solubility, dissolution, absorption and preformulation studies in early drug development |
| 10.45 - 11.45 | Rolf Hilfiker, Solvias AG, Switzerland The importance of choosing optimal solid form of a drug: Salts, co-crystals, polymorphs, amorphous, solvates – Part 1 |
| 11.45 - 12.00 |
Coffee break |
| 12.00 - 13.30 | Rolf Hilfiker, Solvias AG, Switzerland The Importance of choosing optimal solid form of a drug: Salts, co-crystals, polymorphs, amorphous, solvates – Part 2 |
| 13.30 - 15.00 | Lunch |
| 15.00 - 16.30 |
Klara Valko, Bio-mimetic chromatography Ltd. UK |
| 16.30 - 16.45 | Coffee break |
| 16.45 - 18.15 | Tatjana Verbić, University of Belgrade, Serbia Measurements of plasma protein binding – variety of experimental techniques |
| 18.15 - 19.00 | Gaia Colombo, University of Ferrara, Italy Tuning technologies for intranasal drug delivery unravel the multiplicity of achievable therapeutic targets via the nose |
| 19.00 - 19.15 | Coffee break |
| 19.15 - 20.00 | Gaia Colombo, University of Ferrara, Italy Tuning technologies for intranasal drug delivery unravel the multiplicity of achievable therapeutic targets via the nose |
| 20.00 - 21.00 | Sabrina Banella, University of Ferrara, Italy Discovery, characterization and activity of a cisplatin/hyaluronan thin film for loco-regional therapy of cancer |
|
Sunday, September 3, 2023 |
|
| 08.30 - 10.00 | Kiyohiko Sugano, Ritsumeikan University, Japan Basics of modeling and simulation in biopharmaceutics |
| 10.00 - 11.30 | Katarina Nikolić, University of Belgrade, Serbia Computer-aided design of multitarget ligands |
| 11.30 - 11.45 | Coffee break |
| 11.45 - 13.15 | Alex Avdeef, in-ADME Reserch, USA Salt solubility - new Insights from ‘purposeful loitering’ |
| 13.30 - 15.00 | Lunch |
| 15.00 - 16.30 | Abu Serajuddin, St. John’s University, USA Biophamaceutical risk assessment roadmap (BioRAM): Optimization of clinical drug product performance |
| 16.30 - 18.00 | Godefridus Peters, VU University Medical Center, The Netherlands Modern drug development in cancer |
